Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib was effective in treating both early and late onset alopecia areata.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

Created tablet similar to Avodart using γ-cyclodextrin and solubilizers.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Ivarmacitinib effectively regrows hair in severe alopecia areata.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Combining baricitinib with UV-B therapy effectively treats non-segmental vitiligo and is well-tolerated.

Tofacitinib, a hair regrowth treatment, may worsen acne.

Tofacitinib can cause unusual hair growth, requiring careful monitoring and possible laser hair removal.

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

A patient developed nerve problems as a side effect of a hair loss treatment called tofacitinib.

JAK inhibitors offer new hope for treating severe alopecia areata.

Baricitinib was effective and safe for severe hair loss treatment over 6 months.

Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.

Baricitinib is effective and safe for treating severe alopecia areata.

Dextran sulfate was found to be toxic and ineffective for treating HIV.

Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Adalimumab improved folliculitis decalvans in most patients.

The rash resolved after stopping ponatinib.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.